Last Updated: 09/26/2026
Save publications for later
Sign Up
Not sure about your diagnosis?
Check Your Symptoms
Found 9 publications
Lumicitabine, an orally administered nucleoside analog, in infants hospitalized with respiratory syncytial virus (RSV) infection: Safety, efficacy, and pharmacokinetic results.
Journal: PloS one
Published: January 19, 2022
Characterizing the Pharmacokinetic Interaction Between Simeprevir and Odalasvir in Healthy Volunteers Using a Population Modeling Approach.
Journal: The AAPS journal
Published: August 16, 2018
Population Pharmacokinetics of AL-335 and Its Two Main Metabolites (ALS-022399, ALS-022227) in Monotherapy and in Combination with Odalasvir and/or Simeprevir.
Journal: The AAPS journal
Published: July 05, 2018
Respiratory syncytial virus-A dynamics and the effects of lumicitabine, a nucleoside viral replication inhibitor, in experimentally infected humans.
Journal: The Journal of antimicrobial chemotherapy
Published: April 29, 2018
Pharmacokinetics, safety, and tolerability of the 2- and 3-direct-acting antiviral combination of AL-335, odalasvir, and simeprevir in healthy subjects.
Journal: Pharmacology research & perspectives
Published: February 27, 2018
Short-Duration AL-335, Odalasvir, With or Without Simeprevir, in Patients With HCV GT1 or 3 Infection Without Cirrhosis.
Journal: Hepatology (Baltimore, Md.)
Published: February 05, 2018
ALS-008176 for Respiratory Syncytial Virus Infection.
Journal: The New England journal of medicine
Published: April 07, 2016
Activity of Oral ALS-008176 in a Respiratory Syncytial Virus Challenge Study.
Journal: The New England journal of medicine
Published: November 19, 2015
Showing 1-9 of 9
Last Updated: 09/26/2026